What Sumo cold Tablet Treats: Main Uses and Benefits

This combination is generally used for the symptomatic relief of acute episodes related to the common cold and flu-like syndromes. In these conditions, treatment focuses on easing aches, lowering temperature, and unblocking the nose. The tablet is applied in addressing the cluster of symptoms related to physical discomfort, including headache, body aches, and elevated fever, and contributes to easing the overall symptom load.

The combination is commonly used to help with symptoms related to heightened physiological activity, including pain, fever, nasal congestion, and allergic manifestations. This supportive relief assists with maintaining functional stability and supports general well-being during symptomatic phases.

“This combination is intended to provide supportive relief during episodes of heightened discomfort.”

Key Use: Symptom Management This formulation supports patients during acute episodes by managing the symptom clusters of systemic pain, febrile manifestations, nasal blockage, and allergic irritation.

Regulatory References

1. NHS guidance on the Common Cold

Sumo Cold Tablet is generally intended for adults and adolescents, but its use is subject to important precautions and contraindications, primarily due to its combination of active ingredients (Paracetamol, Phenylephrine, Diphenhydramine, and Caffeine).

Who Can Use Sumo Cold Tablet (With Caution)

• Adults and Adolescents: Typically, those aged 12 years and older, for short-term relief of common cold and flu symptoms.
• Patients with Certain Conditions: Individuals with mild to moderate liver or kidney problems, diabetes, or glaucoma should use the tablet only under medical supervision. Dosage adjustment or special monitoring may be necessary.

Special Populations	Recommendation
Pregnancy	Consult a doctor. Not generally recommended unless the potential benefit outweighs the risk to the fetus.
Breastfeeding	Consult a doctor. Not recommended as components may pass into breast milk and potentially harm the infant.

Who Cannot Use Sumo Cold Tablet (Contraindications)

This medication is contraindicated in patients with known hypersensitivity or allergy to any of its components. It should also be avoided by individuals with:

• Severe Organ Dysfunction: Severe liver disease or severe kidney impairment.
• Cardiovascular Conditions: Severe hypertension (high blood pressure) or coronary artery disease.
• Specific Disorders: Hyperthyroidism (overactive thyroid) or closed-angle glaucoma.
• Drug Interactions: Patients currently taking, or who have taken within the last 14 days, Monoamine Oxidase Inhibitors (MAOIs) due to the risk of severe hypertensive reactions. The tablet should not be taken concurrently with other products containing Paracetamol.

Interactions with other medicines and products

Official regulatory information for this combination tablet addresses documented pharmacokinetic and pharmacodynamic interactions.

Contraindicated and High-Risk Combinations:

Classification	Interacting Agents
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs), other Paracetamol-containing products, and other Sympathomimetic Decongestants (due to pressor effects).
Clinically Significant	Oxytocic Drugs (potentiation of pressor effect) and Anticoagulants like Warfarin (increased INR risk with chronic high-dose Paracetamol use).

Pharmacokinetic and Clearance Alterations:

Co-administration with enzyme-inducing drugs, such as certain anticonvulsants or chronic alcohol use, can increase the official risk of Paracetamol hepatotoxicity. The rate of Paracetamol absorption may be increased by Metoclopramide or Domperidone, and reduced by Cholestyramine. Caffeine clearance can be inhibited by specific drugs, potentially increasing exposure. Theophylline co-administration is officially documented to cause a small decrease (16%) in Cetirizine clearance.

Timing and Substance Constraints:

A 14-day separation rule is mandatory before or after the use of MAOIs. To minimize the reduction in Paracetamol absorption, administration should be separated from Cholestyramine. Alcohol and other CNS depressants are officially noted to create a risk of additive CNS depression due to the Cetirizine component.

The Sumo cold Tablet operates across three core mechanistic domains, utilizing a combination of targeted molecular interactions to influence key physiological pathways simultaneously. The overall action profile results from the simultaneous modulation of central nervous system signals, autonomic responses, and peripheral mediator cascades.

Central Regulation of Temperature and Pain Signaling

This domain involves Paracetamol's action to inhibit the COX peroxidase enzyme activity primarily within the CNS, which reduces the synthesis of prostaglandin E2 ( PGE2) in the hypothalamus. This mechanism modulates the body's thermoregulatory set-point, while Caffeine's competitive antagonism of Adenosine A1 and A2A receptors enhances central neuronal activity, influencing the nociceptive pathway.

Dual-Level Modulation of Nasal Congestion

The mechanism modulates vascular and secretory processes via two complementary actions. Phenylephrine acts as an agonist at alpha1 Adrenergic Receptors on nasal blood vessels, initiating smooth muscle contraction (vasoconstriction) which physically reduces mucosal volume. Simultaneously, Cetirizine acts as a selective antagonist of Peripheral Histamine H1 Receptors, blocking the histamine-mediated cascade that influences vascular permeability and exocrine gland activity.

Mechanism Limitations and Specificity

The mechanism of Paracetamol shows specificity for central pain and fever pathways because its COX inhibitory activity is functionally constrained by the high peroxide levels found in inflamed peripheral tissues. Furthermore, while Cetirizine is favored for its low blood-brain barrier penetration, the inclusion of Caffeine's stimulant mechanism provides functional opposition to any low-level, dose-dependent central H1 receptor occupancy.

How to Use Sumo cold Tablet

Administration of the Sumo cold Tablet, a fixed-dose combination (FDC) medicine containing Paracetamol, Cetirizine, Phenylephrine, and Caffeine, is based on established protocols for multi-component cold relief products. Adherence to these guidelines is essential for proper usage.

---

Administration Protocol

The approved route of administration is oral. The tablet unit must be swallowed whole with water and must not be crushed, broken, or chewed. This formulation may be taken with or without food.

Official Dosing and Scheduling

Usage is typically intermittent and based on the recurrence of symptoms. The standard pattern involves administration up to four times daily, with a mandated minimum time interval of four hours between consecutive doses. This interval is critical for preventing the stacking of the active components.

The total amount of medicine taken must not exceed the maximum daily dose specified on the official product label. This constraint is primarily directed at maintaining the safe intake limits for Paracetamol.

Use Restrictions

Constraint	Guideline
Course Duration	Intended for short-term use only, typically restricted to not more than seven consecutive days.
Age Group	Officially designated for use in adults and adolescents aged 12 years and over.

This FDC is not intended for use in pediatric patients under the age of 12. These instructions standardize the approach to using the medicine.

Research Evidence / Overview of Studies for Sumo cold Tablet

---

Evidence for Symptomatic Relief of the Common Cold and Flu-like Syndromes

Research examined this combination tablet in the context of conditions characterized by acute, fluctuating symptoms. The primary study design used was short-term Randomized Controlled Trials (RCTs). These studies were focused on observation periods typically lasting 2 to 5 days. The main goal was to monitor how patients reported their experience and to measure outcomes related to physical discomfort using the Total Symptom Score (TSS). Scientific literature notes that a large portion of the research is based on two- or three-component fixed-dose combinations, not always this exact four-component formulation. Additionally, research focusing on the decongestant component (Phenylephrine) within these combinations was observed in some studies to have mixed findings when compared against a placebo.

---

Evidence for Allergic Rhinitis

The combination was observed in research settings exploring conditions involving periods of heightened symptoms such as acute allergic rhinitis. The research primarily consisted of Phase IV Clinical Studies and Observational Studies, which monitor patient-reported experiences in real-world settings. However, the evidence is limited because this research is often embedded within broader cold and flu treatment data where the allergic component is a co-indication, and dedicated large-scale RCTs focused solely on this indication are fewer.

---

Research Gaps and Follow-up Duration

The acute focus of the available research means the follow-up durations were limited to the typical duration of common cold symptoms. Due to this short-term focus, there is limited information for long-term outcomes or the durability of observed effects. The overall research base relies on findings from similar but not identical combinations, and long-term effects are not fully established.

Key Studies & References Common cold - NHS (Used to establish context on symptomatic care and follow-up duration)

Common questions about Sumo cold Tablet (FAQ)

---

Q: Does this cold medicine cause drowsiness or sleepiness?

Official product labels for cold relief products containing an antihistamine often include a warning that drowsiness or dizziness may occur. Product information includes warnings to use caution when driving or operating heavy machinery until a person knows how the medicine might affect them.

---

Q: Can I take this if I have high blood pressure?

Regulatory documents state that products containing a decongestant like phenylephrine must be used with caution in individuals with pre-existing conditions, including high blood pressure (hypertension). Use is typically prohibited for patients with severe hypertension. For cases other than severe hypertension, official labels generally recommend consulting a healthcare professional before use.

---

Q: Can I take Sumo cold Tablet if I am taking Warfarin (a blood thinner)?

Official information lists warfarin, an anticoagulant (blood thinner), as a clinically significant interaction. The paracetamol component, when taken chronically or at high doses, may increase the risk of bleeding. Because of this risk, official product information often advises that the use of this combination may require closer medical supervision or more frequent monitoring of blood clotting time (INR).

---

Q: What is the reason for the 14-day separation rule with MAOIs?

The mandatory 14-day separation rule is necessary to prevent a dangerous drug-drug interaction with Monoamine Oxidase Inhibitors (MAOIs). This period serves as a washout phase to clear the MAOI from the body, preventing the decongestant component (phenylephrine) from causing a severe and sudden rise in blood pressure known as a hypertensive crisis.

---

Q: Can I stop taking the medicine as soon as my symptoms improve, or do I need to finish the full seven days?

Instructions for short-term symptomatic relief medications typically state that use should be discontinued if symptoms improve or resolve. The full seven-day period represents the maximum recommended duration for use, not a required course of treatment. Official guidance may note that if symptoms worsen or persist past the recommended course, medical advice should be sought.

---

Q: What should I do if I forget to take a dose?

Product labels typically state that if a dose is missed, it can be taken when remembered, unless it is almost time for the next dose. It is important that patients do not take a double dose to compensate for the missed one, and the minimum time interval between administrations should be respected.

How to Store and Dispose of Sumo Cold Tablet

Storage Requirements

Sumo Cold Tablet must be stored in a cool and dry place at controlled room temperature, generally maintained below 30 C. The medicine must be protected from light, moisture, and heat, and storage in direct sunlight or freezers is prohibited. The tablets should be kept in the original container, and the container must be tightly closed to maintain product integrity. As a mandatory safety measure, this medicine must always be stored out of the sight and reach of children and pets. Do not use the tablets after the printed expiry date has passed.

Disposal Instructions

Do not discard expired or unused Sumo Cold Tablet in the household trash or via wastewater without following proper precautions. The preferred method for disposal is to utilize an authorized drug take-back program. If a take-back program is unavailable, unused tablets may be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed bag, and then discarded in the household trash, in accordance with local regulatory guidelines.